BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen ZY, Wang QN, Zhu YH, Zhou LY, Xu T, He ZY, Yang Y. Progress in the treatment of infantile hemangioma. Ann Transl Med 2019;7:692. [PMID: 31930093 DOI: 10.21037/atm.2019.10.47] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Kowalska M, Dębek W, Matuszczak E. Infantile Hemangiomas: An Update on Pathogenesis and Treatment. J Clin Med 2021;10:4631. [PMID: 34682753 DOI: 10.3390/jcm10204631] [Reference Citation Analysis]
2 Kim JH, Lam JM. Paediatrics: how to manage infantile haemangioma. Drugs Context 2021;10:2020-12-6. [PMID: 33889196 DOI: 10.7573/dic.2020-12-6] [Reference Citation Analysis]
3 Lv Z, Yang K, Wang Y. Long non-coding RNA breast cancer-associated transcript 54 sponges microRNA-1269b to suppress the proliferation of hemangioma-derived endothelial cells. Bioengineered 2022;13:6188-95. [PMID: 35200096 DOI: 10.1080/21655979.2022.2027064] [Reference Citation Analysis]
4 Zhou L, Jia X, Yang X. LncRNA-TUG1 promotes the progression of infantile hemangioma by regulating miR-137/IGFBP5 axis. Hum Genomics 2021;15:50. [PMID: 34362467 DOI: 10.1186/s40246-021-00349-w] [Reference Citation Analysis]
5 Rocco R, Cambindo Botto AE, Muñoz MJ, Reingruber H, Wainstok R, Cochón A, Gazzaniga S. Early redox homeostasis disruption contributes to the differential cytotoxicity of imiquimod on transformed and normal endothelial cells. Exp Dermatol 2021. [PMID: 34758172 DOI: 10.1111/exd.14499] [Reference Citation Analysis]
7 Peng W, Liu H, Chen J, Zheng Y, Xu X, Tang H, Liu Q. Development and validation of psychological status questionnaire for parents of infantile hemangiomas. Transl Pediatr 2021;10:3261-72. [PMID: 35070840 DOI: 10.21037/tp-21-554] [Reference Citation Analysis]
8 Pérez-gonzález GL, Cornejo-bravo JM, Vera-graciano R, Adan-lópez ES, Villarreal-gómez LJ. Development, characterization, and in vitro evaluation of adhesive fibrous mat for mucosal propranolol delivery. e-Polymers 2021;22:58-68. [DOI: 10.1515/epoly-2022-0002] [Reference Citation Analysis]
9 Fei Q, Lin Y, Chen X. Treatments for infantile Hemangioma: A systematic review and network meta-analysis.EClinicalMedicine. 2020;26:100506. [PMID: 33089121 DOI: 10.1016/j.eclinm.2020.100506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ali Akbari Ghavimi S, Gehret PM, Aronson MR, Schipani R, Smith KWY, Borek RC, Germiller JA, Jacobs IN, Zur KB, Gottardi R. Drug delivery to the pediatric upper airway. Adv Drug Deliv Rev 2021;174:168-89. [PMID: 33845038 DOI: 10.1016/j.addr.2021.04.004] [Reference Citation Analysis]
11 Qiao J, Lin J, Zhang D, Li J, Chen C, Yu H, Li X, Fang B. Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:554847. [PMID: 33132908 DOI: 10.3389/fphar.2020.554847] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Chottianchaiwat S, Martinez AE, Solman L, Petrof G. Infantile haemangioma presenting in combination with a cerebriform naevus sebaceous on the scalp. Clin Exp Dermatol 2021. [PMID: 34173688 DOI: 10.1111/ced.14758] [Reference Citation Analysis]
13 Shi W, He H, Jiang J, Gao Y, Quan H. Timing and Efficacy of 595-nm Pulsed-Dye Laser Combined with 0.5% Timolol Maleate Solution in the Treatment of Superficial Infantile Hemangiomas. Clin Cosmet Investig Dermatol 2021;14:1593-9. [PMID: 34754209 DOI: 10.2147/CCID.S337850] [Reference Citation Analysis]
14 Cai Y, Ge Y, Ung COL, Li F, Wang J, Xia C, Hu H. Treatment patterns and outcomes in children with infantile hemangiomas: A retrospective observational analysis. SAGE Open Med 2021;9:20503121211056844. [PMID: 34938569 DOI: 10.1177/20503121211056844] [Reference Citation Analysis]
15 Chen J, Wu D, Dong Z, Chen A, Liu S. The expression and role of glycolysis-associated molecules in infantile hemangioma. Life Sci 2020;259:118215. [PMID: 32768579 DOI: 10.1016/j.lfs.2020.118215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Xu X, Wu Y, Li H, Xie J, Cao D, Huang X. Notch pathway inhibitor DAPT accelerates in vitro proliferation and adipogenesis in infantile hemangioma stem cells. Oncol Lett 2021;22:854. [PMID: 34777588 DOI: 10.3892/ol.2021.13115] [Reference Citation Analysis]
17 Xu M, Ouyang T, Lv K, Ma X. Integrated WGCNA and PPI Network to Screen Hub Genes Signatures for Infantile Hemangioma. Front Genet 2020;11:614195. [PMID: 33519918 DOI: 10.3389/fgene.2020.614195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang L, Li S, Gao Q, Lv R, Xu G, Li X, Bi J, Huo R. Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. Head Neck 2021;43:1553-62. [PMID: 33539620 DOI: 10.1002/hed.26625] [Reference Citation Analysis]
19 Shen Z, Zhang D, Li G, Huang D, Qiu Y, Xie C, Zhang X, Wang X, Liu Y. Clinical Characteristics, Classification, and Management of Adult Nasopharyngolaryngeal Hemangioma. Laryngoscope 2021. [PMID: 34160868 DOI: 10.1002/lary.29703] [Reference Citation Analysis]
20 You Y, Li Y, Xiao Y, Zhang J. Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis. Mol Clin Oncol 2021;15:156. [PMID: 34178327 DOI: 10.3892/mco.2021.2318] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wu ZB, Shi SL, Pan FJ, Li L, Chen HY. Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis. Transl Pediatr 2021;10:1867-76. [PMID: 34430434 DOI: 10.21037/tp-21-244] [Reference Citation Analysis]